Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s (AZN) IMFINZI, ...

The 3-year local recurrence rate was 3.6% for transanal TME and 4.4% for laparoscopic TME. The 3-year overall survival was 92 ...

Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.

Second-line therapy with Nal-IRI/5-FU/FA after failure of gemcitabine/nab-paclitaxel in advanced pancreatic cancer (PC): Predictive role of 1st-line therapy (PREDICT ...

The following is a summary of “Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer,” published in the February 2025 ...

Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.

Type I interferon (IFN) score may effectively predict disease progression in limited cutaneous systemic sclerosis, with a ...

Ideaya is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028. Click ...

Tislelizumab plus low-dose nab-paclitaxel “demonstrated enduring efficacy while maintaining a manageable safety profile,” according to researchers.

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival ... in overall survival (OS), a key secondary endpoint in the ...